Jubilant Life Sciences’ Bengaluru-based subsidiary Jubilant Biosys and AstraZeneca have delivered an early stage milestone in the pain therapeutic area, under a collaboration that kicked off two years ago.
Subscribe to our email newsletter
As part of the neuroscience therapeutic area partnership, which is now expanded to cardiovascular and metabolic diseases, Jubilant will deliver a steady stream of preclinical outcomes to AstraZeneca.
AstraZeneca will have the worldwide development and commercialization rights,
Jubilant derives research funding and success-based development and commercialization milestones.